Eiger BioPharmaceuticals (EIGRQ) 10-Q 13 May 14 2014 Q1 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	3 Months Ended
	Mar. 31, 2014	Apr. 25, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	31-Mar-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q1	'
Trading Symbol	'CLDN	'
Entity Registrant Name	'CELLADON CORPORATION	'
Entity Central Index Key	'0001305253	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	18,500,015

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$53,877	$7,903
Short-term investments	3,752	10,467
Prepaid expenses and other assets	585	180
Total current assets	58,214	18,550
Property and equipment, net	353	308
Other assets	11	2,296
Total assets	58,578	21,154
Current liabilities:	'	'
Accounts payable and accrued expenses	1,754	2,908
Accrued clinical expenses	2,208	1,478
Accrued interest	'	14
Convertible notes, net of discount	'	1,044
Warrant liability	'	1,116
Total current liabilities	3,962	6,560
Deferred rent	35	37
Commitments and contingencies	'	'
Stockholders' equity (deficit):	'	'
Preferred stock, $0.001 par value; authorized shares - 10,000,000 and none at March 31, 2014 and December 31, 2013, respectively; no shares issued and outstanding	'	'
Common stock, $0.001 par value; authorized shares - 200,000,000 and 180,000,000 at March 31, 2014 and December 31, 2013, respectively; issued and outstanding - 18,500,015 and 884,179 at March 31, 2014 and December 31, 2013, respectively	18	'
Additional paid-in capital	174,311	61,593
Accumulated other comprehensive income	'	2
Deficit accumulated during the development stage	-119,748	-112,586
Total stockholders' equity (deficit)	54,581	-50,991
Total liabilities, preferred stock and stockholders' equity (deficit)	58,578	21,154
Series A-1 redeemable convertible preferred stock [Member]	'	'
Current liabilities:	'	'
Preferred stock, value	'	60,098
Convertible preferred stock [Member]	'	'
Current liabilities:	'	'
Preferred stock, value	'	$5,450

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Dec. 31, 2013
In Thousands, except Share data, unless otherwise specified			Series A-1 redeemable convertible preferred stock [Member]	Series A-1 redeemable convertible preferred stock [Member]	Convertible preferred stock [Member]	Convertible preferred stock [Member]
Preferred stock, par value	'	'	$0.00	$0.00	$0.00	$0.00
Preferred stock, shares authorized	'	'	0	135,826,497	0	12,138,080
Preferred stock, shares issued	'	'	0	127,140,530	0	12,138,080
Preferred stock, shares outstanding	'	'	0	127,140,530	0	12,138,080
Preferred stock, liquidation preference	'	'	$0	$114,172	$0	$5,450
Preferred stock, par value	$0.00	$0.00	'	'	'	'
Preferred stock, shares authorized	10,000,000	0	'	'	'	'
Preferred stock, shares issued	0	0	'	'	'	'
Preferred stock, shares outstanding	0	0	'	'	'	'
Common stock, par value	$0.00	$0.00	'	'	'	'
Common stock, shares authorized	200,000,000	180,000,000	'	'	'	'
Common stock, shares issued	18,500,015	884,179	'	'	'	'
Common stock, shares outstanding	18,500,015	884,179	'	'	'	'

Consolidated_Statements_of_Ope

Consolidated Statements of Operations and Comprehensive Loss (USD $)	3 Months Ended		159 Months Ended
In Thousands, except Share data, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Operating expenses:	'	'	'
Research and development	$5,218	$2,919	$97,262
General and administrative	1,706	553	21,228
Total operating expenses	6,924	3,472	118,490
Loss from operations	-6,924	-3,472	-118,490
Other income (expense):	'	'	'
Interest income	8	24	683
Interest expense	-59	'	-2,416
Other income (expense)	-4	-82	570
Change in fair value of warrant liability	-183	'	-345
Consolidated net loss	-7,162	-3,530	-119,998
Net loss attributable to non-controlling interest	'	61	250
Net loss attributable to Celladon Corporation	-7,162	-3,469	-119,748
Accretion to redemption value of redeemable convertible preferred stock	'	'	-343
Change in fair value of non-controlling interest	'	-61	-3,259
Deemed dividend	'	'	-856
Net loss attributable to common stockholders	-7,162	-3,530	-124,206
Other comprehensive loss:	'	'	'
Unrealized loss on investments	-2	-3	'
Comprehensive loss	($7,164)	($3,533)	($119,998)
Net loss per share attributable to common stockholders, basic and diluted	($0.60)	($3.99)	'
Weighted-average shares outstanding, basic and diluted	11,939,866	884,179	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	3 Months Ended		159 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013	Mar. 31, 2014
Cash flows from operating activities	'	'	'
Consolidated net loss	($7,162)	($3,530)	($119,998)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation	26	17	499
Stock-based compensation	519	79	3,594
Forgiveness of notes receivable	'	'	72
Noncash interest expense	59	'	2,309
Amortization of investment premium (discount)	13	88	392
Change in fair value of warrant liability	183	'	345
Loss on disposal of property and equipment	'	'	92
Deferred rent	-1	'	44
Changes in operating assets and liabilities:	'	'	'
Prepaid expenses and other assets	-403	-17	-595
Accounts payable and accrued expenses	219	-95	3,840
Net cash used in operating activities	-6,547	-3,458	-109,406
Cash flows from investing activities	'	'	'
Purchases of investment securities	-250	-8,829	-44,861
Proceeds from maturities of investment securities	6,950	9,700	40,717
Purchases of property and equipment	-212	-3	-978
Proceeds from sale of property and equipment	'	'	59
Net cash provided by (used in) investing activities	6,488	868	-5,063
Cash flows from financing activities	'	'	'
Proceeds from issuance of common stock	50,600	'	50,706
Initial public offering costs	-4,567	'	-6,260
Proceeds from issuance of preferred stock, net	'	'	105,822
Proceeds from issuance of exchangeable shares	'	'	4,814
Proceeds from issuance of convertible debt	'	'	13,447
Repayment of convertible debt	'	'	-111
Proceeds from equipment loan	'	'	175
Repayment of equipment loan	'	'	-175
Issuance of notes receivable	'	'	-72
Net cash provided by financing activities	46,033	'	168,346
Net increase (decrease) in cash and cash equivalents	45,974	-2,590	53,877
Cash and cash equivalents, beginning of period	7,903	13,841	'
Cash and cash equivalents, end of period	$53,877	$11,251	$53,877

Basis_of_Presentation_Organiza

Basis of Presentation, Organization and Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

'

Basis of Presentation, Organization and Summary of Significant Accounting Policies

'

1. Basis of Presentation, Organization and Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited consolidated financial statements of Celladon Corporation (Celladon or the Company) should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K (Annual Report) filed with the Securities and Exchange Commission (SEC). The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the fair value of equity awards and clinical trial expense accruals. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Organization

Celladon was incorporated in California on December 21, 2000 (inception) and reincorporated in Delaware in April 2012. The Company is a biotechnology company focused on developing treatments for heart failure, diabetes and neurodegenerative diseases. Celladon’s lead product candidate targets SERCA2a, an enzyme that becomes deficient in patients with heart failure.

As of March 31, 2014, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.

Initial Public Offering

In February 2014, the Company completed its initial public offering of 6,325,000 shares of common stock at an offering price of $8.00 per share, which included the exercise by the underwriters of their option to purchase 825,000 additional shares of common stock. The Company received gross proceeds of $50.6 million and incurred $6.3 million in issuance costs. In connection with the initial public offering, all outstanding shares of convertible preferred stock were converted into shares of common stock, the outstanding principal and accrued interest on the convertible notes were converted into shares of common stock and the unamortized debt discount related to the convertible notes was charged to expense, warrants to purchase shares of Series A-1 preferred stock were converted into warrants to purchase common stock, the warrant liability was reclassified to additional paid-in capital, and the Company’s certificate of incorporation was amended and restated to authorize 200,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock. See Note 6 for additional information.

Principles of Consolidation

In April 2012, Celladon formed a subsidiary, Celladon Europe B.V. (Celladon Europe). From its inception to June 6, 2013 the subsidiary was approximately 90% owned by Celladon and subsequent to June 6, 2013 the subsidiary has been wholly owned by Celladon. The financial statements of Celladon Europe are consolidated with those of the Company. All intercompany transactions and balances are eliminated in consolidation. The U.S. dollar is the functional currency of Celladon Europe. The Company remeasures Celladon Europe’s assets and liabilities related to monetary assets and liabilities to the U.S. dollar and records the net gains or losses resulting from remeasurement in other income (expense) in the consolidated statements of operations and comprehensive loss. Since the formation of Celladon Europe, the Company did not record any material gains or losses from remeasurement.

Investment Securities

Investment securities primarily consist of investment grade corporate debt securities. The Company classifies all investment securities as available-for-sale. Investments with maturity dates greater than 12 months from the end of each reporting period are classified as long-term. Investment securities are carried at fair value, with the unrealized gains and losses reported as a component of other comprehensive income (loss) in stockholders’ equity (deficit) until realized. Realized gains and losses from the sale of investment securities, if any, are determined on a specific identification basis. A decline in the market value of any investment security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. As of March 31, 2014 and December 31, 2013, none of the investment securities have been in an unrealized loss position for more than 12 months. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and are included in interest income. Interest income is recognized when earned.

The following table sets forth the composition of the Company’s investment securities (in thousands):

As of March 31, 2014

Maturity in Years

Amortized

Unrealized

Fair

Cost

Value

Gains

Losses

Corporate debt securities

Less than 1 year

$

3,752

$

—

$

—

$

3,752

As of December 31, 2013

Maturity in Years

Amortized

Unrealized

Fair

Cost

Value

Gains

Losses

Corporate debt securities

Less than 1 year

$

10,465

$

2

$

—

$

10,467

Net Loss Per Share Attributable to Common Stockholders

Basic and diluted net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Potentially dilutive shares, which include convertible preferred stock and rights to acquire convertible preferred stock (non-controlling interest), warrants for the purchase of common stock and options outstanding under the Company’s equity incentive plans, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

Three Months Ended

March 31,

2014

2013

Redeemable convertible preferred stock

—

9,321,385

Convertible preferred stock

—

971,820

Warrants for common stock

231,821

702

Redeemable non-controlling interest

—

857,998

Common stock options

2,060,890

1,323,063

2,292,711

12,474,968

Recent Accounting Pronouncements

In July 2013, the FASB issued Accounting Standards Update (ASU) No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. On January 1, 2014, the Company adopted this standard, which had no impact on its financial position or results of operations.

Celladon_Europe_BV

Celladon Europe B.V.	3 Months Ended
	Mar. 31, 2014
Equity Method Investments And Joint Ventures [Abstract]	'
Celladon Europe B.V.	'
	2. Celladon Europe B.V.
	In April 2012 and June 2012, Cooperatief LSB IV U.A. (LSP) invested an aggregate of $4.8 million in Celladon Europe. In exchange for the investment, the Company issued LSP one share of Special Preferred Voting stock and Celladon Europe issued LSP 1,999 non-voting B shares. The 1,999 B shares were exchangeable into 10,716,405 shares of the Company’s Series A-1 preferred stock at the option of LSP. The Company determined that the investment held by LSP in Celladon Europe should be classified as a redeemable non-controlling interest, as the shares of Celladon Europe were not in-substance common stock. In-substance common stock is an investment in an entity that has risk and reward characteristics that are substantially similar to that entity’s common stock. Due to the liability characteristics associated with the shares of Celladon Europe held by LSP, the Company concluded that LSP’s shares were not substantially similar to common stock. The liability characteristics include LSP’s put rights, which provided LSP with the ability to exchange its shares in Celladon Europe for Series A-1 preferred stock of the Company.
	The redeemable non-controlling interest was initially valued using the fair value of the Series A-1 preferred stock. At each reporting period, the Company adjusted the carrying value of the redeemable non-controlling interest by the net loss attributable to the redeemable non-controlling interest. Any difference between the fair value and the adjusted carrying value of the redeemable non-controlling interest was recorded as an adjustment to additional paid-in capital and presented as a component of net loss attributable to common stockholders in the accompanying consolidated statements of operations and comprehensive loss.
	On June 6, 2013, LSP delivered a notice to exchange its 1,999 B shares of Celladon Europe for 10,716,405 shares of the Company’s Series A-1 preferred stock. Concurrently, the one share of outstanding Special Preferred Voting stock was cancelled. As of June 6, 2013, the redeemable non-controlling interest was adjusted to fair value and reclassified to Series A-1 preferred stock on the accompanying consolidated balance sheet.
	From April 2012 through June 6, 2013, LSP owned approximately 10% of Celladon Europe.
	During the three months ended March 31, 2013, the Company adjusted the loss attributable to common stockholders as a result of increases in the fair value of the redeemable non-controlling interest of approximately $0.1 million. The increase in fair value increased the loss attributable to common stockholders.
	As of March 31, 2014 and December 31, 2013, the $1.3 million and $0.8 million, respectively, of liabilities recognized as a result of consolidating Celladon Europe do not represent additional claims on the Company’s general assets; rather, they represent claims against the specific assets of Celladon Europe. As of March 31, 2014 and December 31, 2013, the $0.3 million and $0.6 million, respectively, of assets recognized as a result of consolidating Celladon Europe do not represent additional assets that could be used to satisfy claims against the Company’s general assets. The assets of Celladon Europe represent the only significant assets of the Company not located in the United States.

Balance_Sheet_Details

Balance Sheet Details	3 Months Ended
	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Balance Sheet Details	'
	3. Balance Sheet Details
	Property and equipment consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Office furniture and other equipment	$	620		$	555
	Accumulated depreciation		(267	)		(247	)
		$	353		$	308
	Accounts payable and accrued expenses consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Accounts payable	$	731		$	1,397
	Current portion of deferred rent		8			8
	Accrued compensation		356			664
	Accrued other		659			839
		$	1,754		$	2,908

Fair_Value_Measurements

Fair Value Measurements	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Measurements	'
	4. Fair Value Measurements
	The Company’s financial instruments primarily consist of cash and cash equivalents, investment securities, accounts payable and accrued liabilities. The carrying value of these financial instruments generally approximates fair value due to their short-term nature. Investment securities are recorded at fair value.
	The accounting guidance defines fair value, establishes a consistent framework for measuring fair value and expands disclosure for each major asset and liability category measured at fair value on either a recurring or nonrecurring basis. Fair value is defined as an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the accounting guidance establishes a three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value as follows:
	Level 1: Observable inputs such as quoted prices in active markets;
	Level 2: Inputs, other than the quoted prices in active markets, that are observable either directly or indirectly; and
	Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions
	As of March 31, 2014 and December 31, 2013, cash and cash equivalents consist primarily of bank deposits with third-party financial institutions and highly liquid money market securities with original maturities at date of purchase of 90 days or less and are stated at cost which approximate fair value and are classified within the Level 1 designation discussed above. Marketable securities are recorded at fair value, defined as the exit price in the principal market in which the Company would transact, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. Level 2 securities are valued using quoted market prices for similar instruments, non-binding market prices that are corroborated by observable market data, or discounted cash flow techniques and include the Company’s investments in corporate debt securities and commercial paper. Financial liabilities that were measured or disclosed at fair value on a recurring basis, and were classified within the Level 3 designation, included the warrant liability and convertible notes prior to their conversion to equity upon the Company’s initial public offering in February 2014. None of the Company’s non-financial assets and liabilities are recorded at fair value on a non-recurring basis. No transfers between levels have occurred during the periods presented.
	Cash equivalents measured at fair value as of March 31, 2014 and December 31, 2013 are all classified within Level 1. Below is a summary of other assets and liabilities measured at fair value (in thousands):
					Fair Value Measurements at
					Reporting Date Using
		As of			Quoted Prices			Significant		Significant
		March 31,			in Active			Other		Unobservable
		2014			Markets for			Observable		Inputs
					Identical			Inputs		(Level 3)
					Assets			(Level 2)
					(Level 1)
	Assets:
	Corporate debt securities	$	3,752		$	—		$	3,752	$	—
					Fair Value Measurements at
					Reporting Date Using
		As of			Quoted Prices			Significant		Significant
		December 31,			in Active			Other		Unobservable
		2013			Markets for			Observable		Inputs
					Identical			Inputs		(Level 3)
					Assets			(Level 2)
					(Level 1)
	Assets:
	Corporate debt securities	$	10,467		$	—		$	10,467	$	—
	Liabilities:
	Convertible notes	$	1,044		$	—		$	—	$	1,044
	Warrant Liability		1,116			—			—		1,116
		$	2,160		$	—		$	—	$	2,160
	The Company determined the fair value of the convertible notes utilizing an estimated cost of debt for comparable venture backed and mezzanine financings.
	The fair value per share of the Company’s underlying Series A-1 preferred stock was used to determine the fair value of the warrant liability. As of December 31, 2013, the fair value of the Series A-1 preferred stock was $0.64 and was derived from the price at which shares were sold in the Company’s initial public offering.
	In addition to the fair value of the underlying Series A-1 preferred stock, the following assumptions were used in the Black-Scholes option pricing model to determine the fair value of the preferred stock warrant liability:
		December 31,
		2013
	Risk-free interest rate		1.58	%
	Expected volatility		82	%
	Expected term (in years)		4.8
	Expected dividend yield		0	%
	The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):
		Convertible			Warrant
		Notes			Liability
	Balance at December 31, 2013	$	1,044		$	1,116
	Changes in fair value		53			183
	Conversion to equity upon initial public offering		(1,097	)		(1,299	)
	Balance at March 31, 2014	$	—		$	—

Commitments_and_Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Commitments and Contingencies	'
	5. Commitments and Contingencies
	Sublicense Agreement and Amended and Restated License Agreement with AmpliPhi
	Sublicense Agreement
	In June 2012, the Company entered into a sublicense agreement (the AmpliPhi Sublicense) with AmpliPhi Biosciences Corporation (AmpliPhi), pursuant to which AmpliPhi sublicensed to the Company certain rights under a separate agreement which AmpliPhi entered into in 2009 with the Trustees of University of Pennsylvania (UPenn). Under the terms of the AmpliPhi Sublicense, the Company obtained an exclusive, worldwide sublicense from AmpliPhi under certain UPenn patents related to AAV1 vectors for the development, manufacture, use and sale of companion diagnostics to MYDICAR. In addition, the Company is required to use commercially reasonable efforts to meet certain developmental, regulatory and commercial milestones with respect to companion diagnostics under the agreement. The Company is currently in compliance with these milestone requirements. In consideration for the sublicense granted to the Company under the agreement, the Company paid to AmpliPhi a sublicense initiation fee of $310,000, and the Company is obligated to pay to AmpliPhi an annual sublicense maintenance fee of $310,000. The Company is also required to pay to AmpliPhi a low single-digit percentage royalty based on net sales of any companion diagnostic covered by a licensed patent sold by the Company, its affiliates or its sublicensees. The Company’s royalty obligations continue on a companion diagnostic-by-companion diagnostic and country-by-country basis until the expiration of the last-to-expire valid claim in a licensed patent covering the applicable companion diagnostic in such country. Finally, the Company is obligated to pay to AmpliPhi all royalty and milestone payments that become due and payable by AmpliPhi to UPenn under AmpliPhi’s agreement with UPenn as a result of the Company’s exercise of the sublicense granted under the Company’s agreement with AmpliPhi, including a low single-digit tiered percentage royalty on net sales of any companion diagnostic sold by the Company, its affiliates or its sublicensees, which royalty is separate from and in addition to the royalty payable to AmpliPhi described above, and up to an aggregate of $850,000 in potential milestone payments per product covered by the licensed patents.
	The Company may unilaterally terminate the agreement upon 30 days’ written notice to AmpliPhi. Absent early termination, the agreement will automatically terminate upon the expiration of the last-to-expire licensed patent, which is expected to be in 2019.
	The Company has recorded research and development expense related to sublicense fees under the agreement of $0.6 million for the period from December 21, 2000 (inception) to March 31, 2014. None of the expense was recorded in the three months ended March 31, 2014 or 2013. Through March 31, 2014, no milestone obligations were incurred under the agreement.
	Amended and Restated License Agreement
	The Company entered into an amended and restated license agreement with AmpliPhi concurrently with the AmpliPhi Sublicense that both amended the terms of the license agreement which the Company entered into with AmpliPhi in 2009 and terminated its manufacturing agreement with AmpliPhi which the Company entered into in 2009. Under the agreement, the Company obtained an exclusive, worldwide license under certain patents and know-how related to AmpliPhi’s AAV vector and manufacturing technology for the development, manufacture, use and sale of MYDICAR. In addition, the Company has agreed to use commercially reasonable efforts to meet certain diligence milestones with respect to the development and commercialization of at least one product covered by the UPenn patent rights licensed to AmpliPhi by UPenn under the Company’s agreement with UPenn.
	The Company is currently in compliance with these milestone requirements. During the term of the agreement, the Company is not obligated to make annual license or maintenance payments, but is obligated to pay to AmpliPhi all royalty and milestone payments that become due and payable by AmpliPhi to UPenn under AmpliPhi’s agreement with UPenn as a result of the Company’s exercise of the sublicense granted under the Company’s agreement with AmpliPhi. This includes a low single-digit tiered percentage royalty on net sales of MYDICAR and any other product covered by the licensed patents sold by the Company, its affiliates or its sublicensees, and up to $850,000 in milestone payments upon the achievement of certain developmental and regulatory milestones related to MYDICAR and any other product covered by the licensed patents. Through March 31, 2014, $0.3 million of milestone obligations were incurred under the agreement. The agreement does not provide either party with termination rights and does not have a provision for expiration or automatic termination.
	Exclusive Patent License with the Regents of the University of Minnesota
	In May 2009, the Company entered into an exclusive patent license agreement with the Regents of the University of Minnesota (UMinn) under which it obtained an exclusive license to UMinn’s joint ownership interest in a patent application related to screening technology for isolation of small molecule modulators of SERCA enzymes. The agreement does not encompass a manufacturing agreement.
	The Company has agreed to meet certain performance milestones under the agreement, the deadline for which may be extended at the Company’s request provided that the Company has used commercially reasonable efforts to achieve such milestones by the applicable deadlines. The Company is currently in compliance with these milestone requirements. The Company has the first right to prosecute and maintain the applicable patent family.
	The Company made an upfront payment to UMinn of $120,000. In addition, the Company is obligated to pay to UMinn an annual license fee of $120,000. The annual license fee will increase to $325,000 if the Company (1) undergoes a change of control, (2) assigns the agreement, any of its rights or obligations under the agreement or as joint ownership interest in the licensed technology, (3) receives a certain amount in license and sublicense revenues under the agreement, (4) files an investigational new drug application, or IND, new drug application, biologic license application or orphan drug application (or a foreign equivalent of any such application) for a product covered by the licensed technology, or (5) enters into any agreement with a third party to market or use the licensed technology, subject to certain exceptions.
	The Company may unilaterally terminate the agreement upon 90 days’ written notice to UMinn. UMinn may terminate the agreement upon 10 days’ written notice to the Company upon the Company’s insolvency or for its breach of the agreement if such breach remains uncured for 90 days after the Company receives notice of such breach, or 30 days in the case of a non-payment breach. Absent early termination, the agreement will automatically terminate upon the expiration of all active claims in any licensed patent or patent application, which is expected to occur no earlier than January 2030.
	The Company has recorded research and development expense related to license and annual maintenance fees under the agreement of $0.6 million for the period from December 21, 2000 (inception) to March 31, 2014. None of the expense was recorded in the three months ended March 31, 2014 or 2013. Through March 31, 2014, no milestone obligations were incurred under the agreement.
	Material Transfer and Exclusivity Agreement
	In February 2014, the Company and Les Laboratoires Servier (Servier) entered into a material transfer and exclusivity agreement, pursuant to which the Company agreed to transfer to Servier samples of certain proprietary compounds from the Company’s small molecule SERCA2b modulator program and granted to Servier a non-exclusive, non-sublicensable, royalty-free license to conduct certain studies of the samples for the purpose of evaluating Servier’s interest in negotiating a potential license and research collaboration agreement with the Company relating to small molecule SERCA2b modulators (Compounds), for the treatment of type 2 diabetes and other metabolic diseases.
	The term of Servier’s license to conduct the evaluation, or the evaluation period, will expire six months after Servier’s initial receipt from the Company of the samples, provided that Servier may extend the evaluation period for up to an additional two months and may terminate the agreement at any time upon written notice to the Company.
	Under the terms of the agreement, the Company also granted to Servier the exclusive right to negotiate for an exclusive, royalty-bearing license to develop and commercialize Compounds, and products containing Compounds, in the field of type 2 diabetes and other metabolic diseases, or the field, solely outside of the United States and its territories and possessions on the terms and conditions set forth in the agreement and other commercially reasonable terms to be negotiated in good faith by the parties and set forth in a definitive license and research collaboration agreement.
	Other License Agreements
	The Company has entered into various license agreements pursuant to which the Company acquired certain intellectual property. Pursuant to each agreement the Company paid a license fee and reimbursed historical patent costs. Additionally, under each agreement, the Company may be required to pay annual maintenance fees, royalties, milestone payments and sublicensing fees. Each of the license agreements is generally cancelable by the Company, given appropriate prior written notice. Minimum annual payments to maintain these cancelable licenses total an aggregate of approximately $0.2 million and potential future milestone payments total an aggregate of approximately $3.3 million. The Company has recorded research and development expense related to license and annual maintenance fees under the agreements of $0.1 million, $0.1 million, and $1.2 million, respectively, for the three months ended March 31, 2014, the three months ended March 31, 2013 and the period from December 21, 2000 (inception) to March 31, 2014.
	Through March 31, 2014, the Company has recorded research and development expense of $0.1 million related to milestone obligations incurred under the agreements.
	Leases
	The Company leases office space in San Diego, California under a long-term operating lease that expires in November 2017. The rent expense for each of the three months ended March 31, 2014 and 2013 was $21,000. Future minimum payments under the long-term operating lease total $345,000.

Stockholders_Equity_Deficit

Stockholders' Equity (Deficit)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Stockholders' Equity (Deficit)	'
	6. Stockholders’ Equity (Deficit)
	Common Stock and Common Stock Warrants
	In February 2014, the Company completed its initial public offering in which it sold 6,325,000 shares of common stock at a public offering price of $8.00 per share.
	Net proceeds from the Company’s initial public offering, shown in the period received or paid, were determined as follows (in thousands):
			Total				Subsequent to				Three months				As of
							March 31,				ended				December 31,
							2014				March 31,				2013
											2014
	Gross proceeds (including over-allotment)		$	50,600			$	—			$	50,600			$	—
	Underwriting discounts and commissions			(3,542	)			—				(3,542	)			—
	Offering costs			(2,805	)			(87	)			(1,025	)			(1,693	)
	Net proceeds		$	44,253			$	(87	)		$	46,033			$	(1,693	)
	In addition, each of the following occurred on February 4, 2014 in connection with the Company’s initial public offering:
		•		Series A-1 redeemable convertible preferred stock outstanding (127,140,530 shares) and Junior preferred convertible stock outstanding (12,138,080 shares) were converted into 10,179,372 and 971,820 shares of the Company’s common stock, respectively;
		•		the outstanding principal balance of $1,097,017 and accrued interest of $20,000 on convertible promissory notes converted into 139,644 shares of the Company’s common stock;
		•		warrants to purchase 2,895,570 shares of Series A-1 preferred stock were converted into warrants to purchase 231,821 shares of the Company’s common stock and the warrant liability was reclassified to additional paid-in capital.
	The following table summarizes the fully exercisable warrants outstanding for the purchase of common stock as of March 31, 2014 and December 31, 2013:
	March 31,				December 31,				Exercise				Expiration
	2014				2013				Price				Date
		—				80			$	224.82				January 2015
		—				622			$	12.49				October 2016
		231,821				—			$	5.61				October 2018
		231,821				702
	Stock Options
	Options granted under our equity incentive plans generally expire no more than ten years from the date of grant and generally vest and become exercisable over a period not to exceed four years, as determined by the board of directors. Recipients of stock options are eligible to purchase shares of the Company’s common stock at an exercise price equal to no less than the estimated fair market value of such stock on the date of grant.
	Prior Plans
	In December 2001, the Company adopted its 2001 Stock Option Plan (the 2001 Plan) and in January 2012 adopted its 2012 Equity Incentive Plan (the 2012 Plan, and together with the 2001 Plan, the Prior Plans). The Prior Plans have terminated and no further shares may be granted under the Prior Plans.
	2013 Equity Incentive Plan
	In October 2013, the Company’s stockholders approved the 2013 Equity Incentive Plan (as amended, the 2013 Plan), which became effective in January 2014. Under the 2013 Plan, the Company may grant stock options, stock appreciation rights, restricted stock, restricted stock units, performance-based stock awards and other awards to individuals who are then employees, officers, non-employee directors or consultants of the Company and its affiliates. Additionally, the 2013 Plan provides for the grant of performance cash awards. Initially, the aggregate number of shares of common stock that may be issued pursuant to stock awards under the 2013 Plan is the sum of (1) 1,473,738 shares, plus (2) the number of shares (not to exceed 1,569,905 shares) (i) the 26,294 shares reserved for issuance under the 2012 Plan at the time the 2013 Plan became effective, and (ii) any shares subject to outstanding stock options or other stock awards that were granted under the Prior Plans that are forfeited, terminate, expire or are otherwise not issued. Additionally, the number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year, beginning on January 1, 2015 and continuing through and including January 1, 2023, by 5% of the total number of shares of the Company’s capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Company’s board of directors.
	A summary of the Company’s stock option activity under the Prior Plans and 2013 Equity Incentive Plan is as follows:
			Options
	Outstanding at December 31, 2013			1,543,667
	Granted			517,223
	Outstanding at March 31, 2014			2,060,890
	2013 Employee Stock Purchase Plan
	In October 2013, the Company’s stockholders approved the 2013 Equity Stock Purchase Plan (ESPP) which became effective in January 2014. Initially, the ESPP authorizes the issuance of 165,732 shares of common stock pursuant to purchase rights granted to the Company’s employees or to employees of any of the Company’s designated affiliates. The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2015 through January 1, 2023 by the least of (1) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (2) 384,307 shares, or (3) a number determined by the Company’s board of directors that is less than (1) and (2).
	Stock-Based Compensation Expense
	The allocation of stock-based compensation for all equity awards is as follows (in thousands):
			Three Months
			Ended
			March 31,
			2014				2013
	Research and development		$	343			$	58
	General and administrative			176				21
			$	519			$	79
	As of March 31, 2014 the unrecognized compensation cost related to outstanding employee options was $5.2 million and is expected to be recognized as expense over approximately 3.2 years.

Basis_of_Presentation_Organiza1

Basis of Presentation, Organization and Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

'

Basis of Presentation

'

Basis of Presentation

The accompanying unaudited consolidated financial statements of Celladon Corporation (Celladon or the Company) should be read in conjunction with the audited financial statements and notes thereto as of and for the year ended December 31, 2013 included in the Company’s Annual Report on Form 10-K (Annual Report) filed with the Securities and Exchange Commission (SEC). The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. In the opinion of management, the accompanying financial statements reflect all adjustments (consisting of normal recurring adjustments) that are necessary for a fair statement of the financial position, results of operations and cash flows for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The preparation of the Company’s consolidated financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company’s consolidated financial statements and accompanying notes. The most significant estimates in the Company’s consolidated financial statements relate to the fair value of equity awards and clinical trial expense accruals. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.

Organization

'

Organization

Celladon was incorporated in California on December 21, 2000 (inception) and reincorporated in Delaware in April 2012. The Company is a biotechnology company focused on developing treatments for heart failure, diabetes and neurodegenerative diseases. Celladon’s lead product candidate targets SERCA2a, an enzyme that becomes deficient in patients with heart failure.

As of March 31, 2014, the Company has devoted substantially all of its efforts to product development, raising capital and building infrastructure and has not generated revenues from its planned principal operations. Accordingly, the Company is considered to be in the development stage.

Initial Public Offering

'

Initial Public Offering

In February 2014, the Company completed its initial public offering of 6,325,000 shares of common stock at an offering price of $8.00 per share, which included the exercise by the underwriters of their option to purchase 825,000 additional shares of common stock. The Company received gross proceeds of $50.6 million and incurred $6.3 million in issuance costs. In connection with the initial public offering, all outstanding shares of convertible preferred stock were converted into shares of common stock, the outstanding principal and accrued interest on the convertible notes were converted into shares of common stock and the unamortized debt discount related to the convertible notes was charged to expense, warrants to purchase shares of Series A-1 preferred stock were converted into warrants to purchase common stock, the warrant liability was reclassified to additional paid-in capital, and the Company’s certificate of incorporation was amended and restated to authorize 200,000,000 shares of common stock and 10,000,000 shares of undesignated preferred stock. See Note 6 for additional information.

Principles of Consolidation

'

Principles of Consolidation

In April 2012, Celladon formed a subsidiary, Celladon Europe B.V. (Celladon Europe). From its inception to June 6, 2013 the subsidiary was approximately 90% owned by Celladon and subsequent to June 6, 2013 the subsidiary has been wholly owned by Celladon. The financial statements of Celladon Europe are consolidated with those of the Company. All intercompany transactions and balances are eliminated in consolidation. The U.S. dollar is the functional currency of Celladon Europe. The Company remeasures Celladon Europe’s assets and liabilities related to monetary assets and liabilities to the U.S. dollar and records the net gains or losses resulting from remeasurement in other income (expense) in the consolidated statements of operations and comprehensive loss. Since the formation of Celladon Europe, the Company did not record any material gains or losses from remeasurement.

Investment Securities

'

Investment Securities

Investment securities primarily consist of investment grade corporate debt securities. The Company classifies all investment securities as available-for-sale. Investments with maturity dates greater than 12 months from the end of each reporting period are classified as long-term. Investment securities are carried at fair value, with the unrealized gains and losses reported as a component of other comprehensive income (loss) in stockholders’ equity (deficit) until realized. Realized gains and losses from the sale of investment securities, if any, are determined on a specific identification basis. A decline in the market value of any investment security below cost that is determined to be other than temporary will result in an impairment charge to earnings and a new cost basis for the security is established. No such impairment charges were recorded for any period presented. As of March 31, 2014 and December 31, 2013, none of the investment securities have been in an unrealized loss position for more than 12 months. Premiums and discounts are amortized or accreted over the life of the related security as an adjustment to yield using the straight-line method and are included in interest income. Interest income is recognized when earned.

The following table sets forth the composition of the Company’s investment securities (in thousands):

As of March 31, 2014

Maturity in Years

Amortized

Unrealized

Fair

Cost

Value

Gains

Losses

Corporate debt securities

Less than 1 year

$

3,752

$

—

$

—

$

3,752

As of December 31, 2013

Maturity in Years

Amortized

Unrealized

Fair

Cost

Value

Gains

Losses

Corporate debt securities

Less than 1 year

$

10,465

$

2

$

—

$

10,467

Net Loss Per Share Attributable to Common Stockholders

'

Net Loss Per Share Attributable to Common Stockholders

Basic and diluted net loss per common share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration for common stock equivalents. Potentially dilutive shares, which include convertible preferred stock and rights to acquire convertible preferred stock (non-controlling interest), warrants for the purchase of common stock and options outstanding under the Company’s equity incentive plans, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.

Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):

Three Months Ended

March 31,

2014

2013

Redeemable convertible preferred stock

—

9,321,385

Convertible preferred stock

—

971,820

Warrants for common stock

231,821

702

Redeemable non-controlling interest

—

857,998

Common stock options

2,060,890

1,323,063

2,292,711

12,474,968

Recent Accounting Pronouncements

'

Recent Accounting Pronouncements

In July 2013, the FASB issued Accounting Standards Update (ASU) No. 2013-11, Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists. ASU 2013-11 provides explicit guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. The guidance is effective prospectively for fiscal years, and interim periods within those years, beginning after December 15, 2013, with an option for early adoption. On January 1, 2014, the Company adopted this standard, which had no impact on its financial position or results of operations.

Basis_of_Presentation_Organiza2

Basis of Presentation, Organization and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2014
Accounting Policies [Abstract]	'
Composition of Investment Securities	'
	The following table sets forth the composition of the Company’s investment securities (in thousands):
	As of March 31, 2014	Maturity in Years		Amortized				Unrealized				Fair
				Cost								Value
								Gains		Losses
	Corporate debt securities	Less than 1 year		$	3,752			$	—	$	—	$	3,752
	As of December 31, 2013	Maturity in Years		Amortized				Unrealized				Fair
				Cost								Value
								Gains		Losses
	Corporate debt securities	Less than 1 year		$	10,465			$	2	$	—	$	10,467
Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders	'
	Potentially dilutive securities not included in the calculation of diluted net loss per share attributable to common stockholders because to do so would be anti-dilutive are as follows (in common stock equivalent shares):
		Three Months Ended
		March 31,
		2014				2013
	Redeemable convertible preferred stock		—				9,321,385
	Convertible preferred stock		—				971,820
	Warrants for common stock		231,821				702
	Redeemable non-controlling interest		—				857,998
	Common stock options		2,060,890				1,323,063
			2,292,711				12,474,968

Balance_Sheet_Details_Tables

Balance Sheet Details (Tables)	3 Months Ended
	Mar. 31, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Summary of Property and Equipment	'
	Property and equipment consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Office furniture and other equipment	$	620		$	555
	Accumulated depreciation		(267	)		(247	)
		$	353		$	308
Summary of Accounts Payable and Accrued Expenses	'
	Accounts payable and accrued expenses consist of the following (in thousands):
		March 31,			December 31,
		2014			2013
	Accounts payable	$	731		$	1,397
	Current portion of deferred rent		8			8
	Accrued compensation		356			664
	Accrued other		659			839
		$	1,754		$	2,908

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	3 Months Ended
	Mar. 31, 2014
Fair Value Disclosures [Abstract]	'
Summary of Other Assets and Liabilities Measured at Fair Value	'
	Below is a summary of other assets and liabilities measured at fair value (in thousands):
					Fair Value Measurements at
					Reporting Date Using
		As of			Quoted Prices			Significant		Significant
		March 31,			in Active			Other		Unobservable
		2014			Markets for			Observable		Inputs
					Identical			Inputs		(Level 3)
					Assets			(Level 2)
					(Level 1)
	Assets:
	Corporate debt securities	$	3,752		$	—		$	3,752	$	—
					Fair Value Measurements at
					Reporting Date Using
		As of			Quoted Prices			Significant		Significant
		December 31,			in Active			Other		Unobservable
		2013			Markets for			Observable		Inputs
					Identical			Inputs		(Level 3)
					Assets			(Level 2)
					(Level 1)
	Assets:
	Corporate debt securities	$	10,467		$	—		$	10,467	$	—
	Liabilities:
	Convertible notes	$	1,044		$	—		$	—	$	1,044
	Warrant Liability		1,116			—			—		1,116
		$	2,160		$	—		$	—	$	2,160
Summary of Assumptions used in Black-Scholes Option Pricing Model	'
	In addition to the fair value of the underlying Series A-1 preferred stock, the following assumptions were used in the Black-Scholes option pricing model to determine the fair value of the preferred stock warrant liability:
		December 31,
		2013
	Risk-free interest rate		1.58	%
	Expected volatility		82	%
	Expected term (in years)		4.8
	Expected dividend yield		0	%
Reconciliation of All Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs	'
	The following table provides a reconciliation of all liabilities measured at fair value using Level 3 significant unobservable inputs (in thousands):
		Convertible			Warrant
		Notes			Liability
	Balance at December 31, 2013	$	1,044		$	1,116
	Changes in fair value		53			183
	Conversion to equity upon initial public offering		(1,097	)		(1,299	)
	Balance at March 31, 2014	$	—		$	—

Stockholders_Equity_Deficit_Ta

Stockholders' Equity (Deficit) (Tables)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Summary of Net Proceeds from Company's Initial Public Offering	'
	Net proceeds from the Company’s initial public offering, shown in the period received or paid, were determined as follows (in thousands):
			Total				Subsequent to				Three months				As of
							March 31,				ended				December 31,
							2014				March 31,				2013
											2014
	Gross proceeds (including over-allotment)		$	50,600			$	—			$	50,600			$	—
	Underwriting discounts and commissions			(3,542	)			—				(3,542	)			—
	Offering costs			(2,805	)			(87	)			(1,025	)			(1,693	)
	Net proceeds		$	44,253			$	(87	)		$	46,033			$	(1,693	)
Summary of Exercisable Warrants Outstanding for Purchase of Common Stock	'
	The following table summarizes the fully exercisable warrants outstanding for the purchase of common stock as of March 31, 2014 and December 31, 2013:
	March 31,				December 31,				Exercise				Expiration
	2014				2013				Price				Date
		—				80			$	224.82				January 2015
		—				622			$	12.49				October 2016
		231,821				—			$	5.61				October 2018
		231,821				702
Summary of Company's Stock Option Activity	'
	A summary of the Company’s stock option activity under the Prior Plans and 2013 Equity Incentive Plan is as follows:
			Options
	Outstanding at December 31, 2013			1,543,667
	Granted			517,223
	Outstanding at March 31, 2014			2,060,890
Schedule of Allocation of Stock-based Compensation for Equity Awards	'
	The allocation of stock-based compensation for all equity awards is as follows (in thousands):
			Three Months
			Ended
			March 31,
			2014				2013
	Research and development		$	343			$	58
	General and administrative			176				21
			$	519			$	79

Basis_of_Presentation_Organiza3

Basis of Presentation, Organization and Summary of Significant Accounting Policies - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	12 Months Ended	159 Months Ended
In Thousands, except Share data, unless otherwise specified	Feb. 28, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014	Jun. 06, 2013
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'	'	'	'	'
Shares sold in initial public offering	6,325,000	'	'	'	'
Initial public offering price per share	$8	'	'	'	'
Underwriters option to purchase additional shares of common stock	825,000	'	'	'	'
Proceeds from issuance of common stock	$50,600	$50,600	'	$50,706	'
Issuance costs	6,300	4,567	'	6,260	'
Authorized shares of common stock	200,000,000	200,000,000	180,000,000	200,000,000	'
Authorized shares of undesignated preferred stock	10,000,000	10,000,000	0	10,000,000	'
Ownership interest, percentage	'	'	'	'	90.00%
Impairment charges on investment securities	'	0	'	'	'
Investment securities, unrealized loss position for more than 12 months	'	$0	$0	'	'

Basis_of_Presentation_Organiza4

Basis of Presentation, Organization and Summary of Significant Accounting Policies - Composition of Investment Securities (Detail) (USD $)	3 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Dec. 31, 2013
Schedule of Available-for-sale Securities [Line Items]	'	'
Fair Value	$3,752	$10,467
Corporate debt securities [Member]	'	'
Schedule of Available-for-sale Securities [Line Items]	'	'
Maturity in Years	'Less than 1 year	'Less than 1 year
Amortized Cost	3,752	10,465
Unrealized Gains	'	2
Unrealized Losses	'	'
Fair Value	$3,752	$10,467

Basis_of_Presentation_Organiza5

Basis of Presentation, Organization and Summary of Significant Accounting Policies - Potentially Dilutive Securities Not Included in Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Detail)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	2,292,711	12,474,968
Redeemable convertible preferred stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	'	9,321,385
Convertible preferred stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	'	971,820
Warrants for common stock [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	231,821	702
Redeemable non-controlling interest [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	'	857,998
Common stock options [Member]	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'
Anti-dilutive securities	2,060,890	1,323,063

Celladon_Europe_BV_Additional_

Celladon Europe B.V. - Additional Information (Detail) (USD $)

3 Months Ended

159 Months Ended

3 Months Ended

0 Months Ended

3 Months Ended

Mar. 31, 2013

Mar. 31, 2014

Jun. 06, 2013

Mar. 31, 2013

Mar. 31, 2014

Dec. 31, 2013

Jun. 06, 2013

Jun. 06, 2013

Jun. 06, 2013

Jun. 06, 2013

Jun. 30, 2012

Apr. 30, 2012

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Europe [Member]

Celladon Corporation [Member]

Special Preferred Voting Stock [Member]

Non-voting B shares [Member]

Series A-1 preferred stock [Member]

LSP [Member]

LSP [Member]

LSP [Member]

LSP [Member]

LSP [Member]

Non-voting B shares [Member]

Series A-1 preferred stock [Member]

Special Preferred Voting Stock [Member]

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate investment

'

'

'

'

'

'

'

'

'

'

$4,800,000

$4,800,000

'

'

'

Shares issued for exchange of investment

'

'

'

'

'

'

'

'

1,999

'

'

'

1,999

'

1

Number of shares exchanged at option

'

'

'

'

'

'

'

'

'

10,716,405

'

'

'

10,716,405

'

Number of shares cancelled

'

'

'

'

'

'

'

1

'

'

'

'

'

'

'

Ownership investment percentage

'

'

90.00%

'

'

'

10.00%

'

'

'

'

'

'

'

'

Increases in fair value of redeemable non-controlling interest

-61,000

-3,259,000

'

100,000

'

'

'

'

'

'

'

'

'

'

'

Liabilities recognized as a result of consolidating Celladon Europe

'

'

'

'

1,300,000

800,000

'

'

'

'

'

'

'

'

'

Assets recognized as a result of consolidating Celladon Europe

'

'

'

'

$300,000

$600,000

'

'

'

'

'

'

'

'

'

Balance_Sheet_Details_Summary_

Balance Sheet Details - Summary of Property and Equipment (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, net	$353	$308
Office furniture and other equipment [Member]	'	'
Property, Plant and Equipment [Line Items]	'	'
Property and equipment, gross	620	555
Property and equipment, accumulated depreciation	-267	-247
Property and equipment, net	$353	$308

Balance_Sheet_Details_Summary_1

Balance Sheet Details - Summary of Accounts Payable and Accrued Expenses (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Statement Of Financial Position [Abstract]	'	'
Accounts payable	$731	$1,397
Current portion of deferred rent	8	8
Accrued compensation	356	664
Accrued other	659	839
Accounts payable and accrued expenses	$1,754	$2,908

Fair_Value_Measurements_Summar

Fair Value Measurements - Summary of Other Assets and Liabilities Measured at Fair Value (Detail) (USD $)	Mar. 31, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Liabilities:	'	'
Liabilities, Fair Value	'	$2,160
Corporate debt securities [Member]	'	'
Assets:	'	'
Assets, Fair Value	3,752	10,467
Convertible notes [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	1,044
Warrant Liability [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	1,116
Level 1 [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	'
Level 1 [Member] | Corporate debt securities [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 1 [Member] | Convertible notes [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	'
Level 1 [Member] | Warrant Liability [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	'
Level 2 [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	'
Level 2 [Member] | Corporate debt securities [Member]	'	'
Assets:	'	'
Assets, Fair Value	3,752	10,467
Level 2 [Member] | Convertible notes [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	'
Level 2 [Member] | Warrant Liability [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	'
Level 3 [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	2,160
Level 3 [Member] | Corporate debt securities [Member]	'	'
Assets:	'	'
Assets, Fair Value	'	'
Level 3 [Member] | Convertible notes [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	1,044
Level 3 [Member] | Warrant Liability [Member]	'	'
Liabilities:	'	'
Liabilities, Fair Value	'	$1,116

Fair_Value_Measurements_Additi

Fair Value Measurements - Additional Information (Detail) (Series A-1 preferred stock [Member], USD $)	12 Months Ended
	Dec. 31, 2013
Series A-1 preferred stock [Member]	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'
Fair value of preferred stock per share derived from IPO	$0.64

Fair_Value_Measurements_Summar1

Fair Value Measurements - Summary of Assumptions used in Black-Scholes Option Pricing Model (Detail) (Series A-1 preferred stock [Member])	12 Months Ended
	Dec. 31, 2013
Series A-1 preferred stock [Member]	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'
Risk-free interest rate	1.58%
Expected volatility	82.00%
Expected term (in years)	'4 years 9 months 18 days
Expected dividend yield	0.00%

Fair_Value_Measurements_Reconc

Fair Value Measurements - Reconciliation of All Liabilities Measured at Fair Value Using Level 3 Significant Unobservable Inputs (Detail) (Level 3 [Member], USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014
Convertible notes [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Balance at December 31, 2013	$1,044
Changes in fair value	53
Conversion to equity upon initial public offering	-1,097
Balance at March 31, 2014	'
Warrant Liability [Member]	'
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]	'
Balance at December 31, 2013	1,116
Changes in fair value	183
Conversion to equity upon initial public offering	-1,299
Balance at March 31, 2014	'

Commitments_and_Contingencies_

Commitments and Contingencies - Additional Information (Detail) (USD $)

3 Months Ended

159 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

159 Months Ended

1 Months Ended

3 Months Ended

159 Months Ended

3 Months Ended

159 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Jun. 30, 2012

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

31-May-09

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2014

Mar. 31, 2013

Mar. 31, 2014

Milestone obligations [Member]

Long-term operating lease [Member]

Long-term operating lease [Member]

AmpliPhi Sublicense [Member]

AmpliPhi Sublicense [Member]

AmpliPhi Sublicense [Member]

AmpliPhi Sublicense [Member]

Exclusive Patent License with the Regents of the University of Minnesota [Member]

Exclusive Patent License with the Regents of the University of Minnesota [Member]

Exclusive Patent License with the Regents of the University of Minnesota [Member]

Exclusive Patent License with the Regents of the University of Minnesota [Member]

Exclusive Patent License with the Regents of the University of Minnesota [Member]

Exclusive Patent License with the Regents of the University of Minnesota [Member]

Exclusive Patent License with the Regents of the University of Minnesota [Member]

Amended and Restated License Agreement [Member]

Other License Agreements [Member]

Other License Agreements [Member]

Other License Agreements [Member]

Insolvency [Member]

Breach of agreement [Member]

Non-payment breach [Member]

Commitments And Contingencies [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Sublicense initiation fee

'

'

'

'

'

'

$310,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Aggregate potential milestone payments

'

'

'

'

'

'

850,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Annual sublicense maintenance fee payable

'

'

'

'

'

'

310,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Notice period given by company for termination of license agreement

'

'

'

'

'

'

'

'30 days

'

'

'

'90 days

'

'

'

'

'

'

'

'

'

License agreement expiration year

'

'

'

'

'

'

'

'2019

'

'

'

'

'

'

'

'

'

'

'

'

'

Research and development expense

5,218,000

2,919,000

97,262,000

100,000

'

'

'

0

0

600,000

'

0

0

600,000

'

'

'

'

100,000

100,000

1,200,000

Milestone obligations incurred

'

'

'

'

'

'

'

0

'

'

'

0

'

'

'

'

'

300,000

'

'

'

Upfront payment

'

'

'

'

'

'

'

'

'

'

120,000

'

'

'

'

'

'

'

'

'

'

Annual license fee

'

'

'

'

'

'

'

'

'

'

120,000

'

'

'

'

'

'

'

'

'

'

Estimated future annual license fee

'

'

'

'

'

'

'

'

'

'

325,000

'

'

'

'

'

'

'

'

'

'

License agreement termination, description

'

'

'

'

'

'

'

'

'

'

'

'The Company may unilaterally terminate the agreement upon 90 daysb written notice to UMinn. UMinn may terminate the agreement upon 10 daysb written notice to the Company upon the Companybs insolvency or for its breach of the agreement if such breach remains uncured for 90 days after the Company receives notice of such breach, or 30 days in the case of a non-payment breach. Absent early termination, the agreement will automatically terminate upon the expiration of all active claims in any licensed patent or patent application, which is expected to occur no earlier than January 2030.

'

'

'

'

'

'

'

'

'

Notice period given to company for termination of license agreement company

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'10 days

'90 days

'30 days

'

'

'

'

Patent expiration period

'

'

'

'

'

'

'

'

'

'

'

'2030-01

'

'

'

'

'

'

'

'

'

Aggregate minimum annual payments to maintain cancelable licenses

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

200,000

'

'

Aggregate potential future milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,300,000

'

3,300,000

Long-term operating lease expiry period

'

'

'

'

'2017-11

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Rent expense

'

'

'

'

21,000

21,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Total future minimum payments under the long-term operating lease

'

'

'

'

$345,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Deficit_Ad

Stockholders' Equity (Deficit) - Additional Information (Detail) (USD $)

0 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

1 Months Ended

3 Months Ended

3 Months Ended

0 Months Ended

Feb. 04, 2014

Feb. 28, 2014

Mar. 31, 2014

Dec. 31, 2013

Feb. 04, 2014

Mar. 31, 2014

Jan. 31, 2014

Mar. 31, 2014

Jan. 31, 2014

Jan. 31, 2014

Mar. 31, 2014

Jan. 31, 2014

Jan. 31, 2014

Mar. 31, 2014

Feb. 04, 2014

Feb. 04, 2014

Feb. 04, 2014

Feb. 04, 2014

Promissory notes [Member]

Prior Plans [Member]

2013 Equity Incentive Plan [Member]

2013 Equity Incentive Plan [Member]

2012 Equity Incentive Plan [Member]

2013 Employee Stock Purchase Plan [Member]

Maximum [Member]

Maximum [Member]

Maximum [Member]

Minimum [Member]

Series A-1 preferred stock [Member]

Common stock [Member]

Series A-1 redeemable convertible preferred stock [Member]

Junior preferred convertible stock [Member]

Stock Options [Member]

Stock Options [Member]

2013 Equity Incentive Plan [Member]

2013 Employee Stock Purchase Plan [Member]

Stock Options [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Shares sold in initial public offering

'

6,325,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Initial public offering price per share

'

$8

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred stock, shares outstanding

'

'

0

0

'

'

'

'

'

'

'

'

'

'

'

'

127,140,530

12,138,080

Preferred stock converted into common stock

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

971,820

10,179,372

Convertible promissory notes, Principle balance outstanding

'

'

'

'

$1,097,017

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible promissory notes, Accrued interest

'

'

'

14,000

20,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Convertible promissory notes converted into common stock

139,644

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Conversion of warrants

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,895,570

231,821

'

'

Options, expiration Period

'

'

'

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

Options, vesting period

'

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

Shares available for grant

'

'

'

'

'

0

'

'

'

'

'

'

'

'

'

'

'

'

Common stock authorized for issuance

'

'

'

'

'

'

1,473,738

'

'

165,732

'

1,569,905

384,307

'

'

'

'

'

Shares reserved for issuance

'

'

'

'

'

'

'

'

26,294

'

'

'

'

'

'

'

'

'

Percentage of common stock outstanding to increase shares reserved for issuance

'

'

'

'

'

'

5.00%

'

'

1.00%

'

'

'

'

'

'

'

'

Common stock reserved for issuance, description

'

'

'The number of shares of common stock reserved for issuance will automatically increase on January 1 of each calendar year, from January 1, 2015 through January 1, 2023 by the least of (1) 1% of the total number of shares of the Company's common stock outstanding on December 31 of the preceding calendar year, (2) 384,307 shares, or (3) a number determined by the Company's board of directors that is less than (1) and (2).

'

'

'

'

'Additionally, the 2013 Plan provides for the grant of performance cash awards. Initially, the aggregate number of shares of common stock that may be issued pursuant to stock awards under the 2013 Plan is the sum of (1) 1,473,738 shares, plus (2) the number of shares (not to exceed 1,569,905 shares) (i) the 26,294 shares reserved for issuance under the 2012 Plan at the time the 2013 Plan became effective, and (ii) any shares subject to outstanding stock options or other stock awards that were granted under the Prior Plans that are forfeited, terminate, expire or are otherwise not issued. Additionally, the number of shares of common stock reserved for issuance under the 2013 Plan will automatically increase on January 1 of each year, beginning on January 1, 2015 and continuing through and including January 1, 2023, by 5% of the total number of shares of the Companybs capital stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by the Companybs board of directors.

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost

'

'

$5,200,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Unrecognized compensation cost expected to be recognized as expense period

'

'

'3 years 2 months 12 days

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Stockholders_Equity_Deficit_Su

Stockholders' Equity (Deficit) - Summary of Net Proceeds from Company's Initial Public Offering (Detail) (USD $)	1 Months Ended	3 Months Ended	159 Months Ended	1 Months Ended	3 Months Ended	12 Months Ended	3 Months Ended
In Thousands, unless otherwise specified	Feb. 28, 2014	Mar. 31, 2014	Mar. 31, 2014	Feb. 28, 2014	Mar. 31, 2014	Dec. 31, 2013	Mar. 31, 2014
				IPO [Member]	IPO [Member]	IPO [Member]	Subsequent Event [Member]
							IPO [Member]
Initial Public Offering [Line Items]	'	'	'	'	'	'	'
Gross proceeds (including over-allotment)	$50,600	$50,600	$50,706	$50,600	$50,600	'	'
Underwriting discounts and commissions	'	'	'	-3,542	-3,542	'	'
Offering costs	-6,300	-4,567	-6,260	-2,805	-1,025	-1,693	-87
Net proceeds	'	'	'	$44,253	$46,033	($1,693)	($87)

Stockholders_Equity_Deficit_Su1

Stockholders' Equity (Deficit) - Summary of Exercisable Warrants Outstanding for Purchase of Common Stock (Detail)	3 Months Ended
	Mar. 31, 2014	Dec. 31, 2013
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	231,821	702
January 2015 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	'	80
Warrants outstanding, Exercise Price	224.82	'
Warrants outstanding, Expiration Date	'2015-01	'
October 2016 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	'	622
Warrants outstanding, Exercise Price	12.49	'
Warrants outstanding, Expiration Date	'2016-10	'
October 2018 [Member]	'	'
Class of Warrant or Right [Line Items]	'	'
Warrants outstanding	231,821	'
Warrants outstanding, Exercise Price	5.61	'
Warrants outstanding, Expiration Date	'2018-10	'

Stockholders_Equity_Deficit_Su2

Stockholders' Equity (Deficit) - Summary of Company's Stock Option Activity (Detail)	3 Months Ended
	Mar. 31, 2014
Equity [Abstract]	'
Options, Outstanding at beginning	1,543,667
Options, Granted	517,223
Options, Outstanding at ending	2,060,890

Stockholders_Equity_Deficit_Sc

Stockholders' Equity (Deficit) - Schedule of Allocation of Stock-based Compensation for Equity Awards (Detail) (USD $)	3 Months Ended
In Thousands, unless otherwise specified	Mar. 31, 2014	Mar. 31, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$519	$79
Research and development [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	343	58
General and administrative [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Stock-based compensation expense	$176	$21